Rezolute (RZLT) vs Shattuck Labs (STTK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Shattuck Labs (STTK) has outperformed Rezolute (RZLT) over the past year, gaining 119.7% versus a loss of 60.1%. Over five years, RZLT leads with a -26.9% price change compared with -52.0% for STTK. Rezolute is the larger company by market cap ($465.6 million vs $454.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RZLT | STTK |
|---|---|---|
| Share price | $3.92 | $4.46 |
| Market cap | $465.58M | $454.22M |
| 1-day change | -6.67% | -1.98% |
| YTD return | +66.10% | +22.19% |
| 1-year return | -60.12% | +119.70% |
| 5-year return | -26.87% | -51.99% |
| EPS (TTM) | $-0.76 | $-0.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.00M |
| Revenue growth (YoY) | — | -82.52% |
| Net income (latest FY) | $-77.60M | $-48.81M |
| Operating margin | — | -5150.80% |
| Net margin | — | -4880.90% |
| 52-week high | $11.17 | $8.33 |
| 52-week low | $1.07 | $1.93 |
| Distance from 52-week high | -64.89% | -46.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +175.51% | +245.29% |
| Average volume | 1.66M | 1.20M |
| Shares outstanding | 118.77M | 101.84M |
| Employees | 63 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STTK has outperformed RZLT by 179.8 percentage points over the past year.
About Rezolute
RZLT stock →Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
About Shattuck Labs
STTK stock →Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.
Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees
RZLT vs STTK FAQ
Which is bigger, Rezolute or Shattuck Labs?
Rezolute (RZLT) is larger, with a market capitalization of $465.58M compared with $454.22M for Shattuck Labs (STTK).
Which stock has performed better over the past year, RZLT or STTK?
STTK returned +119.70% over the past 12 months, compared with -60.12% for RZLT (price return, excluding dividends). Past performance does not predict future results.
Are Rezolute and Shattuck Labs in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.